EUVIMEDEUVIMED entdecken
FallberichtLeserbrief

Erythrodermic dermatomyositis with anti‐TIF1‐γ antibodies

Ke-Yun Tang iD, Hong-Zhong Jin iD

International Journal of Dermatology · 2024

DOI: 10.1111/ijd.17164 ↗

Kurz gefasst

Fallbericht in der Zeitschrift International Journal of Dermatology, 2024. Verfasst von Ke-Yun Tang und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medica…. Hauptthemen laut MEDLINE: Dermatomyositis, Dermatitis, Exfoliative, Autoantibodies, Transcription Factors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 5 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DermatomyositisDermatitis, ExfoliativeAutoantibodiesTranscription FactorsHumansFemaleMaleMiddle Aged

Stichwörter der Autor:innen

amyopathic dermatomyositisanti‐TIF1 autoantibodiesautoimmunitycancerdermatomyositiserythroderma

Substanzen

TRIM33 protein, humanAutoantibodiesTranscription Factors

Autor:innen und Institutionen

  • Department of Dermatology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.

ORCID-Profile: Ke-Yun Tang, Hong-Zhong Jin

Zitieren

APA

Tang, K. Y., & Jin, H. Z. (2024). Erythrodermic dermatomyositis with anti‐TIF1‐γ antibodies. International Journal of Dermatology. https://doi.org/10.1111/ijd.17164

Vancouver

Tang KY, Jin HZ. Erythrodermic dermatomyositis with anti‐TIF1‐γ antibodies. International Journal of Dermatology. 2024. doi:10.1111/ijd.17164

BibTeX
@article{Tang2024,
  author = {Tang, Ke-Yun and Jin, Hong-Zhong},
  title = {Erythrodermic dermatomyositis with anti‐TIF1‐γ antibodies},
  journal = {International Journal of Dermatology},
  year = {2024},
  doi = {10.1111/ijd.17164}
}
Kostenlos starten →